{"id":"abt-335","safety":{"commonSideEffects":[{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PPARδ agonists enhance fatty acid oxidation and improve insulin sensitivity by activating nuclear receptors involved in metabolic regulation. ABT-335 was developed to improve lipid profiles and reduce cardiovascular risk in dyslipidemic patients, particularly those with low HDL cholesterol or elevated triglycerides.","oneSentence":"ABT-335 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that modulates lipid and glucose metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:45.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia with low HDL cholesterol"},{"name":"Hypertriglyceridemia"}]},"trialDetails":[{"nctId":"NCT00616772","phase":"PHASE3","title":"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-02","conditions":"Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia","enrollment":682},{"nctId":"NCT01025492","phase":"PHASE4","title":"Study of Trilipix Effects on Lipids and Arteries","status":"TERMINATED","sponsor":"University of Utah","startDate":"2009-11","conditions":"Dyslipidemia","enrollment":24},{"nctId":"NCT00728910","phase":"PHASE2","title":"Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-06","conditions":"Dyslipidemia","enrollment":25},{"nctId":"NCT00680017","phase":"PHASE3","title":"30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Dyslipidemia, Kidney Disease","enrollment":280},{"nctId":"NCT00463606","phase":"PHASE3","title":"A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-04","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":760},{"nctId":"NCT00728780","phase":"PHASE1","title":"Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-08","conditions":"Adverse Events, Pharmacokinetic Variables","enrollment":32},{"nctId":"NCT00681395","phase":"PHASE1","title":"Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-05","conditions":"Adverse Events, Pharmacokinetic","enrollment":64},{"nctId":"NCT00808678","phase":"PHASE1","title":"Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-12","conditions":"Healthy","enrollment":90},{"nctId":"NCT00826358","phase":"PHASE1","title":"Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Healthy","enrollment":90},{"nctId":"NCT00585143","phase":"PHASE1","title":"Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Dyslipidemia, Renal Insufficiency","enrollment":37},{"nctId":"NCT00487136","phase":"PHASE1","title":"Interaction Between ABT-335, Rosuvastatin and Warfarin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Healthy","enrollment":45},{"nctId":"NCT00491530","phase":"PHASE3","title":"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-06","conditions":"Mixed Dyslipidemia","enrollment":310},{"nctId":"NCT00639158","phase":"PHASE3","title":"Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-02","conditions":"Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia","enrollment":543},{"nctId":"NCT00673881","phase":"PHASE1, PHASE2","title":"ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study","status":"COMPLETED","sponsor":"Radiant Research","startDate":"2008-03","conditions":"Dyslipidemia","enrollment":25},{"nctId":"NCT00681525","phase":"PHASE1","title":"A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-04","conditions":"Pharmacokinetics","enrollment":18},{"nctId":"NCT00839293","phase":"PHASE1","title":"Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-02","conditions":"Healthy","enrollment":32},{"nctId":"NCT00300430","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-09","conditions":"Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia","enrollment":1911},{"nctId":"NCT00300482","phase":"PHASE3","title":"Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-03","conditions":"Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia","enrollment":1445},{"nctId":"NCT00300456","phase":"PHASE3","title":"Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-03","conditions":"Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia","enrollment":657},{"nctId":"NCT00300469","phase":"PHASE3","title":"Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-03","conditions":"Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia","enrollment":613}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"HAEMATURIA"},{"count":2,"reaction":"NON-CARDIAC CHEST PAIN"},{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"APHASIA"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DYSPHAGIA"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":1,"reaction":"GLUCOSE TOLERANCE IMPAIRED"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["fenofibric acid","Choline fenofibrate","Fenofibric acid","Trilipix","TriLipix"],"phase":"phase_3","status":"active","brandName":"ABT-335","genericName":"ABT-335","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-335 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that modulates lipid and glucose metabolism. Used for Dyslipidemia with low HDL cholesterol, Hypertriglyceridemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}